1
|
Glymour MM, Brickman AM, Kivimaki M, Mayeda ER, Chêne G, Dufouil C, Manly JJ. Will biomarker-based diagnosis of Alzheimer's disease maximize scientific progress? Evaluating proposed diagnostic criteria. Eur J Epidemiol 2018; 33:607-612. [PMID: 29948371 PMCID: PMC7571610 DOI: 10.1007/s10654-018-0418-4] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2018] [Accepted: 05/30/2018] [Indexed: 12/14/2022]
Abstract
A recently published framework for the diagnosis of Alzheimer's disease (AD) in research studies would allow diagnosis on the sole basis of two biomarkers (β-amyloid and pathologic tau), even in people with no objective or subjective memory or cognitive changes. This revision will have substantial implications for future Alzheimer's research, and the changes should be rigorously evaluated before widespread adoption. We propose three principles for evaluating any revision to diagnostic frameworks for AD: (1) does the revision improve the validity of the diagnosis; (2) does the revision improve the reliability or reduce the expense of the diagnosis; and (3) will the revision foster innovative and rigorous research across populations. The new diagnostic framework is unlikely to achieve any of these goals. Instead, it has the potential to handicap future researchers, and slow progress towards identifying effective strategies to prevent or treat AD.
Collapse
Affiliation(s)
- Medellena Maria Glymour
- Department of Epidemiology and Biostatistics, University of California, San Francisco, 550 16th Street, San Francisco, CA, 94158, USA.
| | - Adam Mark Brickman
- Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
| | - Mika Kivimaki
- Department of Epidemiology and Public Health, University College London, London, UK
| | - Elizabeth Rose Mayeda
- Department of Epidemiology and Biostatistics, University of California, San Francisco, 550 16th Street, San Francisco, CA, 94158, USA
- Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, USA
| | - Geneviève Chêne
- INSERM U1219-Bordeaux Population Health and CIC1401-EC, ISPED-Bordeaux School of Public Health, INSERM, University of Bordeaux, Bordeaux, France
- CHU de Bordeaux, Pôle de Santé Publique, Bordeaux, France
| | - Carole Dufouil
- INSERM U1219-Bordeaux Population Health and CIC1401-EC, ISPED-Bordeaux School of Public Health, INSERM, University of Bordeaux, Bordeaux, France
- CHU de Bordeaux, Pôle de Santé Publique, Bordeaux, France
| | - Jennifer Jaie Manly
- Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
| |
Collapse
|
2
|
Khachaturian AS. Letter. ALZHEIMER'S & DEMENTIA (AMSTERDAM, NETHERLANDS) 2017; 9:84-87. [PMID: 29255790 PMCID: PMC5725207 DOI: 10.1016/j.dadm.2017.11.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Ara S. Khachaturian
- Corresponding author. Tel.: 301-309-6730; Fax: (844) 309-6730. http://www.alzheimersanddementia.orghttp://adj.edmgr.com
| |
Collapse
|